Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 10722 topiramÁt - potahovaná tableta - 50mg - topiramÁt

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2719 tramadol-hydrochlorid - tableta s prodlouženým uvolňováním - 100mg - tramadol

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2719 tramadol-hydrochlorid - tableta s prodlouženým uvolňováním - 150mg - tramadol

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2719 tramadol-hydrochlorid - tableta s prodlouženým uvolňováním - 200mg - tramadol

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin irsko - 14672 tamsulosin-hydrochlorid - tvrdá tobolka s řízeným uvolňováním - 0,4mg - tamsulosin

Evrópusambandið - tékkneska - EMA (European Medicines Agency)

taw pharma (ireland) limited - hydrochlorid klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidla - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 8500 akarbosa - tableta - 100mg - akarbosa

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 12900 alfuzosin-hydrochlorid - tableta s prodlouženým uvolňováním - 10mg - alfuzosin

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 9568 betaxolol-hydrochlorid - potahovaná tableta - 20mg - betaxolol

Tékkland - tékkneska - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 7653 buprenorfin - transdermální náplast - 35mcg/h - buprenorfin